
Acorda Therapeutics ACOR
Quarterly report 2024-Q1
added 05-14-2024
Acorda Therapeutics Operating Cycle 2011-2026 | ACOR
Annual Operating Cycle Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 394 | 236 | 264 | 361 | 306 | 125 | 151 | 182 | 167 | 151 | 177 | 164 | 184 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 394 | 125 | 220 |
Quarterly Operating Cycle Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 381 | 417 | - | 166 | 195 | 314 | - | 198 | 258 | 273 | - | 250 | 448 | 709 | 39.9 | 330 | 285 | 328 | 30.9 | 120 | 101 | 192 | 39.4 | 52.7 | 53.3 | 51.1 | - | 35.1 | 37.4 | 33 | - | 19.4 | 25.2 | 29.1 | - | 27.7 | 30.3 | 35.7 | - | 33.1 | 32.3 | 36.3 | - | 31 | 31.8 | 31.5 | - | 22.4 | 31.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 709 | 19.4 | 144 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
15.1 K | $ 4.2 | -2.67 % | $ 298 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
AVEO Pharmaceuticals
AVEO
|
111 | - | - | $ 521 M | ||
|
Apellis Pharmaceuticals
APLS
|
115 | $ 20.61 | -1.67 % | $ 2.6 B | ||
|
Agenus
AGEN
|
4.13 | $ 3.33 | - | $ 1.19 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 28.87 | -4.5 % | $ 1.67 B | ||
|
bluebird bio
BLUE
|
127 | - | - | $ 546 M | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M |